Drug Profile


Alternative Names: AF 37702; EPO mimetic - Affymax; Erythropoetin mimetic - Affymax; Hematide; Omontys; Peginesatide acetate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Affymax
  • Developer Affymax; Takeda
  • Class Antianaemics; Peptides; Polyethylene glycols
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Anaemia
  • Discontinued Aplastic anaemia; Chemotherapy-induced anaemia

Most Recent Events

  • 30 Oct 2014 Discontinued - Phase-II for Anaemia in Europe (SC)
  • 30 Oct 2014 Discontinued - Phase-II for Anaemia in Russia (Parenteral)
  • 30 Oct 2014 Discontinued - Phase-II for Aplastic anaemia in France, Germany and United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top